Tuesday, October 1, 2024 at 2-3pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Please join Sanofi Specialty Care for a physician/pharmacist-led discussion on Chronic Obstructive Pulmonary Disease (COPD) with type 2 inflammation. We will review a patient case focused on COPD with type 2 inflammation and how this drives exacerbations and readmissions. Updated 2024 GOLD guidelines will be discussed. We will review dupilumab Phase 3 studies in COPD with type 2 inflammation and discuss implications for our patient case and potential to decrease healthcare resource utilization.

Learning Objectives

• Provide an overview of COPD including pathophysiology and disease burden.
• Describe the role of exacerbations and type 2 inflammation in driving COPD disease burden.
• Discuss 2024 GOLD Guidelines for COPD diagnosis, classification, and management.
• Review Phase 3 studies of dupilumab in COPD with type 2 inflammatio (BOREAS/NOTUS).

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.